Literature DB >> 25223407

Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases.

Christien Rondaan1, Aalzen de Haan, Gerda Horst, J Cordelia Hempel, Coretta van Leer, Nicolaas A Bos, Sander van Assen, Marc Bijl, Johanna Westra.   

Abstract

OBJECTIVE: Patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (Wegener's) (GPA) have a 3-20-fold increased risk of herpes zoster compared to the general population. The aim of this study was to evaluate if susceptibility is due to decreased levels of cellular and/or humoral immunity to the varicella-zoster virus (VZV).
METHODS: A cross-sectional study of VZV-specific immunity was performed in 38 SLE patients, 33 GPA patients, and 51 healthy controls. Levels of IgG and IgM antibodies to VZV were measured using an in-house glycoprotein enzyme-linked immunosorbent assay (ELISA). Cellular responses to VZV were determined by interferon-γ (IFNγ) enzyme-linked immunospot (ELISpot) assay and carboxyfluorescein succinimidyl ester (CFSE) dye dilution proliferation assay.
RESULTS: Levels of IgG antibodies to VZV were increased in SLE patients as compared to healthy controls, but levels of IgM antibodies to VZV were not. Antibody levels in GPA patients did not differ significantly from levels in healthy controls. In response to stimulation with VZV, decreased numbers of IFNγ spot-forming cells were found among SLE patients (although not GPA patients) as compared to healthy controls. Proliferation of CD4+ T cells in response to stimulation with VZV was decreased in SLE patients but not GPA patients.
CONCLUSION: SLE patients have increased levels of IgG antibodies against VZV, while cellular immunity is decreased. In GPA patients, antibody levels as well as cellular responses to VZV were comparable to those in healthy controls. These data suggest that increased prevalence of herpes zoster in SLE patients is due to a poor cellular response. Vaccination strategies should aim to boost cellular immunity against VZV.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25223407     DOI: 10.1002/art.38804

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  15 in total

1.  Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.

Authors:  C Rondaan; C C van Leer; S van Assen; H Bootsma; K de Leeuw; S Arends; N A Bos; J Westra
Journal:  Lupus       Date:  2018-04-18       Impact factor: 2.911

2.  Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study.

Authors:  Shin-Yi Tsai; Hsuan-Ju Chen; Chon-Fu Lio; Hui-Ping Ho; Chien-Feng Kuo; Xiaofeng Jia; Chi Chen; Yu-Tien Chen; Yi-Ting Chou; Tse-Yen Yang; Fang-Ju Sun; Leiyu Shi
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

3.  Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report.

Authors:  Masato Habuka; Yoko Wada; Yoichi Kurosawa; Suguru Yamamoto; Yusuke Tani; Riuko Ohashi; Yoichi Ajioka; Masaaki Nakano; Ichiei Narita
Journal:  BMC Res Notes       Date:  2018-03-05

Review 4.  Infection in systemic lupus erythematosus, similarities, and differences with lupus flare.

Authors:  Ju-Yang Jung; Chang-Hee Suh
Journal:  Korean J Intern Med       Date:  2017-04-28       Impact factor: 2.884

5.  VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs.

Authors:  David Schub; Gunter Assmann; Urban Sester; Martina Sester; Tina Schmidt
Journal:  Arthritis Res Ther       Date:  2018-11-09       Impact factor: 5.156

Review 6.  Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

Authors:  Kunihiro Yamaoka
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

7.  National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia.

Authors:  Sara G Murray; Gabriela Schmajuk; Laura Trupin; Lianne Gensler; Patricia P Katz; Edward H Yelin; Stuart A Gansky; Jinoos Yazdany
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

8.  Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis.

Authors:  Christien Rondaan; Kornelis S M van der Geest; Elisabeth Eelsing; Annemieke M H Boots; Nicolaas A Bos; Johanna Westra; Elisabeth Brouwer
Journal:  Front Immunol       Date:  2017-10-24       Impact factor: 7.561

Review 9.  Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature.

Authors:  Lei Wang; Erik A M Verschuuren; Coretta C van Leer-Buter; Stephan J L Bakker; Anoek A E de Joode; Johanna Westra; Nicolaas A Bos
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

Review 10.  From Severe Herpes Zoster to Rare Suid Herpesvirus Encephalitis: A New Twist of the Varicellovirus Genus Infection in Patients with Kidney Diseases.

Authors:  Yan Zhang; Ming Hu; Dong Wei; Hui Zhang; Bao Chu; Hao-Ming Xu; Tao Wang
Journal:  Int J Med Sci       Date:  2020-03-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.